0001562180-15-000731.txt : 20150908
0001562180-15-000731.hdr.sgml : 20150907
20150908162319
ACCESSION NUMBER: 0001562180-15-000731
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150908
FILED AS OF DATE: 20150908
DATE AS OF CHANGE: 20150908
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tokai Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 255 STATE STREET
STREET 2: 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 617-225-4348
MAIL ADDRESS:
STREET 1: 255 STATE STREET
STREET 2: 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kalowski Lee
CENTRAL INDEX KEY: 0001618273
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 151097066
MAIL ADDRESS:
STREET 1: C/O TOKAI PHARMACEUTICALS, INC.
STREET 2: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2015-09-08
false
0001404281
Tokai Pharmaceuticals Inc
TKAI
0001618273
Kalowski Lee
C/O TOKAI PHARMACEUTICALS, INC.
255 STATE STREET 6TH FLOOR
BOSTON
MA
02109
false
true
false
false
Chief Financial Officer
Common Stock
2015-09-08
4
S
false
4668.00
13.13
D
40953.00
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.11 to $13.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.
/s/ Cindy Driscoll, Attorney-in-Fact
2015-09-08